The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants

Dr. David Edward Marcinko MBA MEd

SPONSOR: http://www.HealthDictionarySeries.org

***

***

During the late 2010s, interest in psychedelic‑based therapies expanded rapidly in the United States, driven by emerging clinical research suggesting potential benefits for conditions such as major depression, post‑traumatic stress disorder, and substance‑use disorders. Within this context, the U.S. Department of Health and Human Services (HHS) under President Donald J. Trump oversaw several developments that contributed to a faster regulatory environment for certain psychedelic compounds. While the administration did not create a dedicated psychedelic policy framework, its broader approach to medical innovation, combined with specific regulatory decisions, helped accelerate the review and potential therapeutic use of substances like psilocybin and MDMA.

One of the most significant factors shaping this landscape was the administration’s emphasis on reducing regulatory barriers in health care and speeding access to experimental treatments. The Right‑to‑Try Act, signed into law in 2018, reflected this philosophy. Although the law was not written specifically for psychedelic compounds, it signaled a federal willingness to allow patients with life‑threatening conditions to pursue investigational therapies outside traditional FDA pathways. This broader deregulatory posture created an environment in which researchers, advocacy groups, and drug developers felt increased momentum to push for accelerated review of psychedelic‑based treatments.

At the same time, the Food and Drug Administration (FDA), which operates under HHS, took several notable steps that directly affected psychedelic research. The agency granted “Breakthrough Therapy” designations to MDMA‑assisted psychotherapy for PTSD and to psilocybin‑assisted therapy for treatment‑resistant depression. These designations are reserved for therapies that show substantial improvement over existing treatments in early trials, and they commit the FDA to providing intensive guidance and expedited review. Although the FDA’s decisions are based on scientific criteria rather than political direction, they occurred during the Trump administration and aligned with its broader emphasis on accelerating medical innovation.

The Breakthrough Therapy designations were especially important because they signaled federal recognition of the therapeutic potential of psychedelic compounds after decades of regulatory stagnation. For MDMA, the designation supported Phase 3 clinical trials, which moved forward with increased coordination between researchers and regulators. For psilocybin, the designation encouraged additional investment and expanded clinical research infrastructure. These steps did not legalize the substances, but they significantly shortened the timeline for potential approval by creating a more collaborative and responsive regulatory process.

***

***

Another relevant development was the administration’s focus on addressing the national mental health and addiction crises. Policymakers and health officials frequently emphasized the need for new tools to combat rising rates of depression, suicide, and opioid addiction. This urgency created a policy climate in which unconventional or previously stigmatized treatments received more serious consideration. While psychedelic therapies were not a central component of federal mental health strategy, the broader push for innovation helped normalize discussions about alternative therapeutic approaches.

HHS also oversaw agencies such as the National Institutes of Health (NIH), which began showing renewed interest in psychedelic research. Although NIH funding for psychedelic studies remained limited, the agency’s public statements acknowledged growing scientific evidence and the need for further investigation. This shift in tone, even without major funding changes, contributed to a sense that federal institutions were becoming more open to exploring psychedelic‑based therapies.

In addition to regulatory and scientific developments, cultural and political attitudes toward psychedelics were evolving rapidly during this period. Several cities and states began considering or implementing decriminalization measures, and public opinion polls showed increasing support for therapeutic access. While these changes occurred largely at the local and state levels, they influenced national conversations and added momentum to federal regulatory developments. The Trump administration did not directly shape these local policies, but the broader national climate of reevaluating drug policy intersected with federal actions that supported faster review of psychedelic therapies.

It is also important to note that the administration’s approach to drug policy was not uniformly deregulatory. Federal law continued to classify psychedelics as Schedule I substances, and enforcement priorities varied across agencies. However, the combination of FDA designations, a deregulatory stance toward medical innovation, and growing scientific evidence created a unique moment in which psychedelic therapies advanced more rapidly through the regulatory pipeline than at any point in the previous half‑century.

COMMENTS APPRECIATED

EDUCATION: Books

SPEAKING: Dr. Marcinko will be speaking and lecturing, signing and opining, teaching and preaching, storming and performing at many locations throughout the USA this year! His tour of witty and serious pontifications may be scheduled on a planned or ad-hoc basis; for public or private meetings and gatherings; formally, informally, or over lunch or dinner. All medical societies, financial advisory firms or Broker-Dealers are encouraged to submit an RFP for speaking engagements: CONTACT: Ann Miller RN MHA at MarcinkoAdvisors@outlook.com -OR- http://www.MarcinkoAssociates.com

Like, Refer and Subscribe

***

***

Filed under: iMBA, Inc. | Tagged: david marcinko | Leave a comment »

Dr. David Edward Marcinko MBA MEd

***

***

A Turning Point for Global Stock and Bond Markets

The first quarter of 2026 unfolded as a dramatic and often unsettling period for global financial markets. What began as a continuation of the optimism that characterized late 2025 quickly transformed into a quarter defined by volatility, geopolitical tension, and shifting expectations for monetary policy. Both the stock market and the bond market experienced meaningful reversals, revealing the fragility of investor confidence and the sensitivity of modern markets to global disruptions. By the end of March, the quarter had become a case study in how quickly sentiment can change and how interconnected the world’s financial systems truly are.

A Strong Start Meets Sudden Turbulence

January opened with a sense of momentum. Inflation had been easing steadily in many major economies, and investors entered the year expecting central banks—especially the Federal Reserve—to begin cutting interest rates by mid‑year. Corporate earnings from the final quarter of 2025 were generally solid, and consumer spending remained resilient. Equity indices in the United States, Europe, and parts of Asia climbed to new highs in the first weeks of the year, supported by strong labor markets and improving business sentiment.

But this early optimism proved short‑lived. In late February, escalating conflict in the Middle East triggered a sharp rise in oil prices and a wave of risk aversion across global markets. The disruption of shipping routes and the threat of broader regional instability forced investors to reassess inflation expectations and the likelihood of near‑term rate cuts. What had been a smooth upward trajectory for equities quickly turned into a period of pronounced volatility.

U.S. Stock Market: A Quarter of Repricing

The U.S. stock market, which had been the global leader for much of the previous year, experienced a notable pullback. The S&P 500, after reaching record highs in mid‑January, ended the quarter lower as investors rotated out of high‑growth technology stocks and into more defensive sectors. The technology sector, which had dominated market performance for several years, faced renewed scrutiny. Concerns grew that the rapid expansion of artificial intelligence could disrupt established business models, creating winners and losers in ways that were not yet fully understood.

At the same time, rising energy prices placed pressure on corporate margins and revived fears of inflation. Companies that had benefited from lower input costs in 2025 suddenly faced a more challenging environment. As a result, investors began favoring value‑oriented sectors such as energy, industrials, and materials. Energy stocks, in particular, surged as oil prices climbed sharply in March, benefiting from both higher demand and constrained supply.

Small‑cap stocks, which had lagged large‑cap names for much of the previous year, showed signs of renewed strength. With valuations more attractive and earnings expectations stabilizing, smaller companies drew interest from investors seeking opportunities outside the crowded mega‑cap space. Still, the overall tone of the U.S. market remained cautious, and the quarter closed with equities broadly lower than where they began.

International Equities: Divergent Regional Outcomes

Outside the United States, equity markets delivered mixed results. European stocks struggled under the weight of rising energy costs and concerns about economic growth. The continent’s reliance on imported energy made it particularly vulnerable to disruptions in global supply chains, and the spike in oil and gas prices reignited fears of a slowdown. Consumer confidence weakened, and business surveys pointed to softer activity in manufacturing and services.

In contrast, Japan emerged as one of the strongest performers of the quarter. The combination of a weaker yen, strong export demand, and political stability helped lift Japanese equities. Investors also responded positively to expectations that the government would pursue growth‑oriented policies following a decisive political victory early in the year. The result was a rare bright spot in an otherwise challenging global landscape.

Emerging markets experienced a more nuanced quarter. Early gains in countries such as South Korea and Taiwan, driven by strength in semiconductor and technology‑related industries, were later offset by the broader risk‑off sentiment that followed the Middle East conflict. While emerging markets did not fall as sharply as some developed markets, they ended the quarter slightly negative overall.

Bond Markets: A Reversal of Expectations

The bond market experienced its own form of turbulence. At the start of the year, yields had been drifting lower as investors anticipated a series of interest rate cuts. But the sudden rise in energy prices and the renewed threat of inflation forced a rapid reassessment. Instead of preparing for easing, markets began to price in the possibility that central banks might delay or even reconsider rate cuts altogether.

U.S. Treasury yields rose across the curve, with short‑term yields increasing the most as expectations for near‑term policy changes shifted. The broad U.S. bond market declined as a result, marking one of its weakest quarters since the tightening cycle began several years earlier. Corporate bonds also faced pressure, particularly in the investment‑grade segment, where higher yields reduced the value of existing debt.

Global bonds outside the United States followed a similar pattern, though the declines were somewhat less severe. Many international central banks faced the same dilemma: inflation risks were rising again just as policymakers had hoped to begin normalizing rates. The result was a cautious stance that kept yields elevated and bond prices under pressure.

Commodities: The Quarter’s Clear Winner

If equities and bonds struggled, commodities—especially energy—were the clear winners of the quarter. Oil prices surged dramatically in March, driven by supply disruptions and heightened geopolitical risk. This rise had ripple effects across the global economy, influencing inflation expectations, corporate earnings forecasts, and consumer sentiment. Other commodities, including grains and industrial metals, also saw gains as shipping routes were disrupted and demand patterns shifted.

Conclusion: A Quarter Defined by Uncertainty

The first quarter of 2026 demonstrated how quickly financial conditions can change and how sensitive markets remain to geopolitical and economic shocks. Stocks and bonds both faced headwinds, while commodities surged. Investors were reminded that diversification, risk management, and adaptability are essential in navigating an increasingly complex global environment. As the world moved into the second quarter, the central questions revolved around inflation, interest rates, and the possibility of further geopolitical escalation—factors that would continue to shape market behavior in the months ahead.

COMMENTS APPRECIATED

EDUCATION: Books

SPEAKING: Dr. Marcinko will be speaking and lecturing, signing and opining, teaching and preaching, storming and performing at many locations throughout the USA this year! His tour of witty and serious pontifications may be scheduled on a planned or ad-hoc basis; for public or private meetings and gatherings; formally, informally, or over lunch or dinner. All medical societies, financial advisory firms or Broker-Dealers are encouraged to submit an RFP for speaking engagements: CONTACT: Ann Miller RN MHA at MarcinkoAdvisors@outlook.com -OR- http://www.MarcinkoAssociates.com

Like, Refer and Subscribe

***

***

Filed under: iMBA, Inc. | Tagged: david marcinko | Leave a comment »